Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

317 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A therapeutic window for platelet reactivity for patients undergoing elective percutaneous coronary intervention: results of the ARMYDA-PROVE (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity for Outcome Validation Effort) study.
Mangiacapra F, Patti G, Barbato E, Peace AJ, Ricottini E, Vizzi V, Gatto L, D'Ambrosio A, De Bruyne B, Wijns W, Di Sciascio G. Mangiacapra F, et al. JACC Cardiovasc Interv. 2012 Mar;5(3):281-9. doi: 10.1016/j.jcin.2012.01.009. JACC Cardiovasc Interv. 2012. PMID: 22440493 Free article.
Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) study.
Patti G, Nusca A, Mangiacapra F, Gatto L, D'Ambrosio A, Di Sciascio G. Patti G, et al. J Am Coll Cardiol. 2008 Sep 30;52(14):1128-33. doi: 10.1016/j.jacc.2008.06.038. J Am Coll Cardiol. 2008. PMID: 18804738 Free article. Clinical Trial.
Short-term, high-dose Atorvastatin pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the ARMYDA-CIN [atorvastatin for reduction of myocardial damage during angioplasty--contrast-induced nephropathy] trial.
Patti G, Ricottini E, Nusca A, Colonna G, Pasceri V, D'Ambrosio A, Montinaro A, Di Sciascio G. Patti G, et al. Am J Cardiol. 2011 Jul 1;108(1):1-7. doi: 10.1016/j.amjcard.2011.03.001. Epub 2011 Apr 27. Am J Cardiol. 2011. PMID: 21529740 Clinical Trial.
Comparison of safety and efficacy of bivalirudin versus unfractionated heparin in high-risk patients undergoing percutaneous coronary intervention (from the Anti-Thrombotic Strategy for Reduction of Myocardial Damage During Angioplasty-Bivalirudin vs Heparin study).
Patti G, Pasceri V, D'Antonio L, D'Ambrosio A, Macrì M, Dicuonzo G, Colonna G, Montinaro A, Di Sciascio G. Patti G, et al. Am J Cardiol. 2012 Aug 15;110(4):478-84. doi: 10.1016/j.amjcard.2012.04.017. Epub 2012 May 12. Am J Cardiol. 2012. PMID: 22583760 Clinical Trial.
317 results